固形がん患者を対象としたE7090の第1相試験

基本情報

NCT ID

NCT02275910

ステータス

完了

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

40

治験依頼者名

Eisai Inc.

概要

This is a Phase 1 study of E7090 in subjects with advanced solid tumors. This study will be conducted in 2 parts: 1. Part 1 will be the dose escalation portion of this study to determine the maximum tolerated dose in subjects with solid tumors, and 2. Part 2 will comprise cohort expansions to further characterize the safety and tolerability of E7090 and to assess preliminary efficacy of E7090 in subjects with solid tumors characterized by genetic abnormalities in FGF/FGFR pathway.

対象疾患

介入

依頼者（Sponsor）